PharmGKB summary: Abacavir pathway

Pharmacogenetics and Genomics

Volumn 24, Issue 5, 2014, Pages 276-282

  Barbarino, Julia M ^a   Kroetz, Deanna L ^c   Altman, Russ B ^a,b   Klein, Teri E ^a  

^a Departments of Bioengineering and Genetics   (United States)

^b STANFORD UNIVERSITY   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ALCOHOL; HEAT SHOCK PROTEIN 70; HLA B57 ANTIGEN; LAMIVUDINE; PEGINTERFERON; RIBAVIRIN; ZIDOVUDINE; 2',3' DIDEOXYNUCLEOSIDE DERIVATIVE;

ALLELE; ARTICLE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG ELIMINATION; DRUG MECHANISM; DRUG METABOLISM; DRUG SOLUBILITY; HOST CELL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MITOCHONDRIAL DNA REPLICATION; PHARMACODYNAMICS; PHARMACOGENETICS; PREDICTIVE VALUE; PRIORITY JOURNAL; TABLET; METABOLISM;

DIDEOXYNUCLEOSIDES; HUMANS; PHARMACOGENETICS;

EID: 84898540382     PISSN: 17446872     EISSN: 17446880     Source Type: Journal    
DOI: 10.1097/FPC.0000000000000040     Document Type: Article

References (53)

1. Thompson MA, Aberg JA, Hoy JF, Telenti A, Benson C, Cahn P, et al. Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral Society-USA panel. JAMA 2012; 308:387-402.
2. Yuen GJ,Weller S, Pakes GE. A review of the pharmacokinetics of abacavir. Clin Pharmacokinet 2008; 47:351-371.
3. Martin MA, Klein TE, Dong BJ, Pirmohamed M, Haas DW, Kroetz DL, et al. Clinical pharmacogenetics implementation consortium guidelines for HLA-B genotype and abacavir dosing. Clin Pharmacol Ther 2012; 91:734-738.
4. Mallal S, Nolan D,Witt C, Masel G, Martin AM, Moore C, et al. Association between presence of HLA-B5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir. Lancet 2002; 359:727-732.
5. Escaut L, Liotier JY, Albengres E, Cheminot N, Vittecoq D. Abacavir rechallenge has to be avoided in case of hypersensitivity reaction. AIDS 1999; 13:1419-1420.
6. Ma JD, Lee KC, Kuo GM. HLA-B57:01 testing to predict abacavir hypersensitivity. PLoS Curr 2010; 2:RRN1203.
7. Stocchi L, Cascella R, Zampatti S, Pirazzoli A, Novelli G, Giardina E. The pharmacogenomic HLA biomarker associated to adverse abacavir reactions: comparative analysis of different genotyping methods. Curr Genomics 2012; 13:314-320.
8. Swen JJ, Nijenhuis M, de Boer A, Grandia L, Maitland-van der Zee AH, Mulder H, et al. Pharmacogenetics: from bench to byte - an update of guidelines. Clin Pharmacol Ther 2011; 89:662-673.
9. D:A:D Study Group, Sabin CA,Worm SW, Weber R, Reiss P, El-Sadr W, et al. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration. Lancet 2008; 371:1417-1426.
10. Lang S, Mary-Krause M, Cotte L, Gilquin J, Partisani M, Simon A, et al. Impact of individual antiretroviral drugs on the risk of myocardial infarction in human immunodeficiency virus-infected patients: a case-control study nested within the French Hospital Database on HIV ANRS cohort CO4. Arch Intern Med 2010; 170:1228-1238.
11. Obel N, Farkas DK, Kronborg G, Larsen CS, Pedersen G, Riis A, et al. Abacavir and risk of myocardial infarction in HIV-infected patients on highly active antiretroviral therapy: a population-based nationwide cohort study. HIV Med 2010; 11:130-136.
12. Strategies for Management of Anti-Retroviral Therapy/INSIGHT, DAD Study Groups. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients. AIDS 2008; 22:F17-F24.
13. Ding X, Andraca-Carrera E, Cooper C, Miele P, Kornegay C, Soukup M, et al. No association of abacavir use with myocardial infarction: findings of an FDA meta-analysis. J Acquir Immune Defic Syndr 2012; 61:441-447.
14. McDowell JA, Lou Y, Symonds WS, Stein DS. Multiple-dose pharmacokinetics and pharmacodynamics of abacavir alone and in combination with zidovudine in human immunodeficiency virus-infected adults. Antimicrob Agents Chemother 2000; 44:2061-2067.
15. Joly V, Descamps D, Yeni P. NNRTI plus PI combinations in the perspective of nucleoside-sparing or nucleoside-failing antiretroviral regimens. AIDS Rev 2002; 4:128-139.
16. Barry M, Mulcahy F, Merry C, Gibbons S, Back D. Pharmacokinetics and potential interactions amongst antiretroviral agents used to treat patients with HIV infection. Clin Pharmacokinet 1999; 36:289-304.
17. McDowell JA, Chittick GE, Stevens CP, Edwards KD, Stein DS. Pharmacokinetic interaction of abacavir (1592U89) and ethanol in human immunodeficiency virus-infected adults. Antimicrob Agents Chemother 2000; 44:1686-1690.
18. Bani-Sadr F, Denoeud L, Morand P, Lunel-Fabiani F, Pol S, Cacoub P, et al. Early virologic failure in HIV-coinfected hepatitis C patients treated with the peginterferon-ribavirin combination: does abacavir play a role? J Acquir Immune Defic Syndr 2007; 45:123-125.
19. Vispo E, Barreiro P, Pineda JA, Mira JA, Maida I, Martin-Carbonero L, et al. Low response to pegylated interferon plus ribavirin in HIV-infected patients with chronic hepatitis C treated with abacavir. Antivir Ther 2008; 13:429-437.
20. Mira JA, Lopez-Cortes LF, Barreiro P, Tural C, Torres-Tortosa M, de Los Santos Gil I, et al. Efficacy of pegylated interferon plus ribavirin treatment in HIV/hepatitis C virus co-infected patients receiving abacavir plus lamivudine or tenofovir plus either lamivudine or emtricitabine as nucleoside analogue backbone. J Antimicrob Chemother 2008; 62:1365-1373.
21. Amorosa VK, Slim J, Mounzer K, Bruno C, Hoffman-Terry M, Dorey-Stein Z, et al. The influence of abacavir and other antiretroviral agents on virological response to HCV therapy among antiretroviral-treated HIV-infected patients. Antivir Ther 2010; 15:91-99.
22. Pineda JA, Mira JA, Gil Ide L, Valera-Bestard B, Rivero A, Merino D, et al. Influence of concomitant antiretroviral therapy on the rate of sustained virological response to pegylated interferon plus ribavirin in hepatitis C virus/HIV-coinfected patients. J Antimicrob Chemother 2007; 60:1347-1354.
23. Laufer N, Laguno M, Perez I, Cifuentes C, Murillas J, Vidal F, et al. Abacavir does not influence the rate of virological response in HIV-HCV-coinfected patients treated with pegylated interferon and weight-adjusted ribavirin. Antivir Ther 2008; 13:953-957.
24. Solas C, Pambrun E,Winnock M, Salmon D, Poizot-Martin I, Dominguez S, et al. Ribavirin and abacavir drug interaction in HIV-HCV coinfected patients: fact or fiction? AIDS 2012; 26:2193-2199.
25. Chittick GE, Gillotin C, McDowell JA, Lou Y, Edwards KD, Prince WT, et al. Abacavir: absolute bioavailability, bioequivalence of three oral formulations, and effect of food. Pharmacotherapy 1999; 19:932-942.
26. Daluge SM, Good SS, Faletto MB, Miller WH St, Clair MH, Boone LR, et al. 1592U89, a novel carbocyclic nucleoside analog with potent, selective antihuman immunodeficiency virus activity. Antimicrob Agents Chemother 1997; 41:1082-1093.
27. McDowell JA, Chittick GE, Ravitch JR, Polk RE, Kerkering TM, Stein DS. Pharmacokinetics of [(14)C]abacavir, a human immunodeficiency virus type (HIV-1) reverse transcriptase inhibitor, administered in a single oral dose to HIV-1-infected adults: a mass balance study. Antimicrob Agents Chemother 1999; 43:2855-2861.
28. Faletto MB, Miller WH, Garvey EP St, Clair MH, Daluge SM, Good SS. Unique intracellular activation of the potent anti-human immunodeficiency virus agent 1592U89. Antimicrob Agents Chemother 1997; 41: 1099-1107.
29. Balzarini J, Naesens L, De Clercq E. New antivirals - mechanism of action and resistance development. Curr Opin Microbiol 1998; 1:535-546.
30. Miller WH, Daluge SM, Garvey EP, Hopkins S, Reardon JE, Boyd FL, et al. Phosphorylation of carbovir enantiomers by cellular enzymes determines the stereoselectivity of antiviral activity. J Biol Chem 1992; 267: 21220-21224.
31. Richman DD. HIV chemotherapy. Nature 2001; 410:995-1001.
32. Kakuda TN. Pharmacology of nucleoside and nucleotide reverse transcriptase inhibitor-induced mitochondrial toxicity. Clin Ther 2000; 22:685-708.
33. Mallal S, Phillips E, Carosi G, Molina JM, Workman C, Tomazic J, et al. HLA-B5701 screening for hypersensitivity to abacavir. N Engl J Med 2008; 358:568-579.
34. Martin AM, Almeida CA, Cameron P, Purcell AW, Nolan D, James I, et al. Immune responses to abacavir in antigen-presenting cells from hypersensitive patients. AIDS 2007; 21:1233-1244.
35. Janeway CAJ, Travers P, Walport M, Shlomchik MJ. Antigen recognition by T cells. In: Janeway CAJ, editor. Immunobiology: the immune system in health and disease. New York: Garland Science; 2001.
36. Janeway CAJ, Travers P, Walport M, Shlomchik MJ. The major histocompatibility complex and its functions. In: Janeway CAJ, editor. Immunobiology: the immune system in health and disease. New York: Garland Science; 2001.
37. Hetherington S, Hughes AR, Mosteller M, Shortino D, Baker KL, Spreen W, et al. Genetic variations in HLA-B region and hypersensitivity reactions to abacavir. Lancet 2002; 359:1121-1122.
38. Hughes DA, Vilar FJ, Ward CC, Alfirevic A, Park BK, Pirmohamed M. Costeffectiveness analysis of HLA B5701 genotyping in preventing abacavir hypersensitivity. Pharmacogenetics 2004; 14:335-342.
39. Waters LJ, Mandalia S, Gazzard B, Nelson M. Prospective HLA-B 5701 screening and abacavir hypersensitivity: a single centre experience. AIDS 2007; 21:2533-2534.
40. Zucman D, Truchis P, Majerholc C, Stegman S, Caillat-Zucman S. Prospective screening for human leukocyte antigen-B5701 avoids abacavir hypersensitivity reaction in the ethnically mixed French HIV population. J Acquir Immune Defic Syndr 2007; 45:1-3.
41. Rauch A, Nolan D, Martin A, McKinnon E, Almeida C, Mallal S. Prospective genetic screening decreases the incidence of abacavir hypersensitivity reactions in the Western Australian HIV cohort study. Clin Infect Dis 2006; 43:99-102.
42. Hughes AR, Mosteller M, Bansal AT, Davies K, Haneline SA, Lai EH, et al. Association of genetic variations in HLA-B region with hypersensitivity to abacavir in some, but not all, populations. Pharmacogenomics 2004; 5:203-211.
43. Cao K, Hollenbach J, Shi X, Shi W, Chopek M, Fernandez-Vina MA. Analysis of the frequencies of HLA-A, B, and C alleles and haplotypes in the five major ethnic groups of the United States reveals high levels of diversity in these loci and contrasting distribution patterns in these populations. Hum Immunol 2001; 62:1009-1030.
44. Saag M, Balu R, Phillips E, Brachman P, Martorell C, Burman W, et al. High sensitivity of human leukocyte antigen-b5701 as a marker for immunologically confirmed abacavir hypersensitivity in white and black patients. Clin Infect Dis 2008; 46:1111-1118.
45. Pichler WJ, Beeler A, Keller M, Lerch M, Posadas S, Schmid D, et al. Pharmacological interaction of drugs with immune receptors: the p-i concept. Allergol Int 2006; 55:17-25.
46. Ostrov DA, Grant BJ, Pompeu YA, Sidney J, Harndahl M, Southwood S, et al. Drug hypersensitivity caused by alteration of the MHC-presented selfpeptide repertoire. Proc Natl Acad Sci USA 2012; 109:9959-9964.
47. Illing PT, Vivian JP, Dudek NL, Kostenko L, Chen Z, Bharadwaj M, et al. Immune self-reactivity triggered by drug-modified HLA-peptide repertoire. Nature 2012; 486:554-558.
48. Norcross MA, Luo S, Lu L, Boyne MT, Gomarteli M, Rennels AD, et al. Abacavir induces loading of novel self-peptides into HLA-B57: 01: an autoimmune model for HLA-associated drug hypersensitivity. AIDS 2012; 26:F21-F29.
49. Hewitt EW. The MHC class I antigen presentation pathway: strategies for viral immune evasion. Immunology 2003; 110:163-169.
50. Chessman D, Kostenko L, Lethborg T, Purcell AW,Williamson NA, Chen Z, et al. Human leukocyte antigen class I-restricted activation of CD8 + T cells provides the immunogenetic basis of a systemic drug hypersensitivity. Immunity 2008; 28:822-832.
51. Tavaria M, Gabriele T, Kola I, Anderson RL. A hitchhiker's guide to the human Hsp70 family. Cell Stress Chaperones 1996; 1:23-28.
52. Milner CM, Campbell RD. Polymorphic analysis of the three MHC-linked HSP70 genes. Immunogenetics 1992; 36:357-362.
53. Martin AM, Nolan D, Gaudieri S, Almeida CA, Nolan R, James I, et al. Predisposition to abacavir hypersensitivity conferred by HLA-B5701 and a haplotypic Hsp70-HOM variant. Proc Natl Acad Sci USA 2004; 101:4180-4185.